Editor’s note: LimeLight is a regular feature from WRAL TechWire offering another means of publishing noteworthy news. Be sure to check out more LimeLight worthy news at this link.


RESEARCH TRIANGLE PARK – GSK and ViiV Healthcare [majority owned by GSK] will share new data on its industry-leading infectious diseases pipeline and portfolio at the Infectious Disease Society of America’s IDWeek 2023 annual meeting in Boston, US from 11-15 October 2023.

Data from 47 abstracts will be presented in total, which will focus on scientific developments in a range of infectious diseases, including seasonal respiratory viruses, HIV, and chronic viral infections, affecting large patient populations.

Eleven abstracts have been accepted across GSK’s world-leading vaccines portfolio, including the first scientific presentation of Respiratory Syncytial Virus (RSV) vaccine efficacy and safety data over two full RSV seasons, which has been accepted for oral presentation on 13 October 2023 at 1:45 ET, as well as data on the role of meningococcal B vaccine recommendation on gonorrhea public health impact in older adolescents.

WRAL TechWire LimeLight Social Sharing Image

An additional 23 abstracts will be presented by ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer, Inc. and Shionogi & Co., Ltd. as shareholders, and its research partners, advancing knowledge in the areas of treatment, prevention, and improving the care of specific patient populations. Of note, the ABOVE clinical trial, which highlights real-world adherence and persistence data of ViiV Healthcare’s long-acting, two drug regimen against other therapies, will be presented on 12 October 2023 at 3:00 ET.

Tony Wood, Chief Scientific Officer, GSK, said: “We are proud to share new data from across our infectious diseases portfolio at this year’s IDWeek. Of the more than 2.5 billion people we will reach this decade, a significant majority will be through this portfolio. Our abstracts demonstrate our focus on the prevention and treatment of infections, and on the care pathway to ensure our vaccines and medicines reach those who need them. We look forward to connecting with the scientific community to determine how we can continue to develop innovative solutions to prevent and treat bacterial, viral and other infections in areas of unmet need.”

In infectious diseases, GSK has pioneered innovation for more than 70 years. Infectious diseases are a significant global burden, responsible for one in six deaths worldwide1. They affect everyone, everywhere, and this is a major concern for patients and society. Around one billion people are infected annually by seasonal respiratory viruses such as RSV2, influenza3 and COVID-194, and many require hospitalisation, with those who live with underlying health conditions at increased risk. About 38 million people live with HIV worldwide, many of whom still face stigma and do not have adequate access to care. Millions of individuals are also struggling with bacterial and fungal infections, while hundreds of millions live with chronic viral conditions like hepatitis B. The breadth of data presented at IDWeek across these disease areas reinforces GSK and ViiV Healthcare’s goal to revolutionise the prevention and treatment of infection, enhancing the quality of life for billions of people around the world.

IDWeek data summary

GSK and ViiV Healthcare sponsored and supported studies to be presented at IDWeek 2023 can be found here.